MagnesiumFreeze Sciatic Nerve Claims Evaluated: Consumer Research Report Examines Magnesium Niacinamide Relief Topical Cream Ingredients, NAD+ Science, and Sciatic Nerve Support Discussions




MagnesiumFreeze Sciatic Nerve Claims Evaluated: Consumer Research Report Examines Magnesium Niacinamide Relief Topical Cream Ingredients, NAD+ Science, and Sciatic Nerve Support Discussions

A 2026 informational consumer research report examining MagnesiumFreeze (Magnesium Niacinamide Relief) topical nerve support claims, ingredient research context, pricing disclosures, and verification considerations for consumers researching sciatic nerve support products and topical nerve support creams

Spearfish, SD, March 06, 2026 (GLOBE NEWSWIRE) — This article is an informational consumer research report and does not constitute medical, health, or treatment advice. All product details described below are stated as presented by the company and should be verified directly on the official website before making any decision about the product. This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. In this report, the term “effectiveness” refers strictly to how the company’s marketing language describes potential outcomes. It does not indicate that the finished product has been clinically proven effective, and no published clinical trial appears to evaluate MagnesiumFreeze (Magnesium Niacinamide Relief) as a proprietary formula.

Why Consumers Are Researching Topical Nerve Support Products in 2026

Interest in topical nerve support products has continued to expand as more adults explore non-pharmaceutical approaches to localized discomfort, cellular energy support, and magnesium-based topical formulas. For many people over 50, the overlap between persistent nerve sensitivity, declining cellular nutrient levels, and limited conventional options feels frustrating — and the search for topical alternatives that complement existing care keeps growing.

Consumers researching sciatic nerve discomfort online have increasingly encountered topical nerve support formulas marketed around NAD+ metabolism, magnesium-based delivery systems, and transdermal nutrient support. Search queries such as “Magnesium Niacinamide Relief ingredients,” “MagnesiumFreeze cream information,” “topical NAD+ nerve pain,” “magnesium cream for sciatica,” and “sciatic nerve topical relief” have grown as more people explore options beyond conventional pain management.

MagnesiumFreeze (Magnesium Niacinamide Relief) is one product appearing in these searches, particularly among individuals researching topical creams positioned around NAD+ metabolism and magnesium-based nerve support. The company’s advertising references Nobel Prize-winning nerve research, NAD+ biology, and a topical delivery method it calls the “Transdermal Refuel” approach — a positioning that understandably generates questions about what the formula actually contains and whether those ingredients have credible research behind them.

This 2026 consumer research report examines publicly available marketing statements associated with MagnesiumFreeze (Magnesium Niacinamide Relief), ingredient-level scientific literature, and company-published policy information to clarify what is supported by published research and what should be independently verified. This report does not evaluate MagnesiumFreeze as a medical treatment.

Interest in topical nerve support products has expanded alongside broader consumer attention to cellular energy metabolism, inflammation research, magnesium deficiency, and localized topical comfort formulas. Products positioned around NAD+ biology and transdermal delivery now sit within a growing category of nerve support creams and topical wellness products discussed across consumer health searches.

Current product details, pricing, and terms can be confirmed by viewing the current Magnesium Niacinamide Relief offer (official Peak Health Research page).

Individual results vary. Topical products are not substitutes for professional medical evaluation, prescribed treatment, or physician-guided pain management. Consult a qualified healthcare provider before starting any new product for nerve-related discomfort.

What Is Magnesium Niacinamide Relief

Magnesium Niacinamide Relief is a topical cream marketed as a nerve support formula designed for people dealing with sciatic nerve discomfort. According to the company, Peak Health Research, the product delivers magnesium and niacinamide (a form of vitamin B3) through the skin as part of its topical nerve support positioning.

The product falls within the broader category of topical nerve support creams, a segment that includes magnesium lotions, botanical anti-inflammatory creams, and transdermal nutrient delivery formulas marketed for localized discomfort.

The product is distributed by Nutra Hero LLC, based in Spearfish, South Dakota. According to the company’s terms and conditions, the corporate address is 41 W Highway 14, Ste 1763, Spearfish, SD 57783. The product label identifies it as a Magnesium Chloride Cream for Relief and Recovery.

The company markets the product under the Peak Health Research brand and describes its team as including doctors, athletes, nutritionists, and functional health experts. According to the company’s website, its stated mission centers on combining natural formulas with scientific research to support the body’s natural healing processes. The promotional materials are presented as authored by “Dr. Andy Salazar,” described as a licensed pain specialist serving as Medical Director of Peak Health Research. This report has not independently verified those credentials.

Scientific Research Background: NAD+ Metabolism and Nerve Cell Health

Before getting into what the company claims, it helps to understand the science the marketing is built on — because there is real science here, even if the connection to this specific product requires careful examination.

NAD+ (nicotinamide adenine dinucleotide) is a well-established coenzyme found in every living cell. It plays a central role in cellular energy production, DNA repair, and the activation of sirtuins — proteins associated with cellular longevity and repair mechanisms. This is not fringe science. This area of research has become increasingly relevant in discussions around aging, neuronal resilience, and cellular repair support. NAD+ biology is one of the most actively studied areas in aging and neuroscience research today.

Published research confirms that NAD+ levels decline with age, and this decline is associated with changes in mitochondrial function, cellular repair capacity, and neuronal health. A comprehensive review published in the International Journal of Molecular Sciences documented that NAD+ metabolism has a direct influence on neuronal survival and that altered NAD+ pathways are implicated in several neurodegenerative conditions.

Separately, a review published through the National Center for Biotechnology Information (PMC) examining nicotinamide’s influence on central nervous system health found that the compound appears to play a role in protecting neurons from traumatic injury and ischemia. The review noted that nicotinamide’s neuroprotective capacity has been linked to its ability to restore intracellular NAD+ and ATP levels and to inhibit overactivation of PARP — an enzyme that, when overactivated, depletes NAD+ and leads to cell death.

Magnesium is an essential mineral involved in hundreds of biochemical processes. Published research has examined magnesium’s role in nerve conduction, muscle relaxation, and inflammatory modulation. Magnesium deficiency — which becomes more common with aging — has been associated with heightened nerve sensitivity and muscle cramping in published literature.

Here is where context matters most: the majority of NAD+ research has focused on oral supplementation using precursors like NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), not topical niacinamide application. And while niacinamide is a recognized NAD+ precursor, the extent to which topically applied niacinamide can meaningfully impact NAD+ levels in deep nerve tissue has not been established through published clinical evidence.

The science behind NAD+ and nerve health is legitimate. Whether a topical cream can deliver these compounds at meaningful concentrations to sciatic nerve tissue is a separate question — and one that currently lacks published clinical data specific to this product.

Ingredient Analysis: What the Formula Contains

According to the company’s published product information, Magnesium Niacinamide Relief contains three primary active ingredients. Here is what published research says about each one individually — keeping in mind that ingredient-level research does not necessarily reflect outcomes from the finished product formulation, which has not been independently evaluated in published clinical trials.

Magnesium Niacinamide

According to the company, this compound is included to support cellular NAD+ levels — described by the brand as the “energy molecule” nerve cells need for proper function and repair signaling. The company states that this ingredient helps replenish vital cellular components and addresses what it describes as underlying nerve cell nutrient depletion.

Niacinamide (nicotinamide) is a well-documented NAD+ precursor in published research. Studies have confirmed its role in cellular energy production and neuronal protection. However, most published research has studied niacinamide through oral administration, not topical delivery to deep tissue. The specific concentration of magnesium niacinamide per application is not disclosed on available product materials.

Arnica

Arnica is a botanical compound with a long history of traditional use for pain and inflammation. A 2021 review published in Medicines (MDPI) examined clinical trials testing arnica for pain management across conditions including post-operative pain, arthritis, and musculoskeletal discomfort. The review concluded that arnica extract and topical preparations containing arnica showed promising effects for pain relief, attributed to anti-inflammatory, antioxidant, and immunomodulatory properties.

A separate randomized, double-blind study found that topical arnica gel was not inferior to topical ibuprofen for osteoarthritis of the hands over a 21-day treatment period. Research results for arnica have been mixed overall — some studies show benefit while others show minimal effect — but the compound has a substantial research history for topical anti-inflammatory applications.

Boswellia

Boswellia is an herbal extract from the Boswellia serrata tree, researched for its potential role in modulating inflammatory pathways through compounds called boswellic acids. According to the brand, boswellia is included to protect nerves from long-term damage and help prevent scar tissue buildup. Published research has examined boswellic acids for anti-inflammatory properties, though most clinical studies have focused on oral supplementation for joint health rather than topical application for nerve-specific outcomes.

These findings relate to ingredient research conducted under controlled study conditions rather than published clinical trials of the finished Magnesium Niacinamide Relief product.

MagnesiumFreeze Marketing Claims vs. What Research Can Confirm

The company’s website positions MagnesiumFreeze with language that includes references to “Nobel Prize-winning research,” a “Transdermal Refuel” method, and claims of 15-minute relief timelines. These are the company’s marketing claims as presented on the product page.

Here is what that means in practical terms for someone doing their due diligence:

The marketing materials reference ingredients studied in relation to NAD+ metabolism, nerve cell health, and inflammatory modulation. Some of those individual ingredients do have published research behind them — particularly niacinamide as an NAD+ precursor and arnica for topical anti-inflammatory applications. That research is real, and it is worth understanding.

However, there is a distinction worth drawing carefully. Ingredient-level research conducted on isolated compounds at specific dosages is not the same as clinical evidence that this particular topical cream formulation produces the outcomes described in the marketing materials. No published clinical trial appears to evaluate MagnesiumFreeze (Magnesium Niacinamide Relief) as a finished proprietary formula using the standard of a randomized, placebo-controlled trial.

That distinction applies broadly across the topical wellness product category — it is not unique to this product. But understanding it puts you in a stronger position to evaluate what you are actually buying.

Company Claim: “Sciatic Nerve Decay” is the underlying cause of most sciatic pain

According to the promotional materials, declining NAD+ levels cause nerve cells to “starve” and fire pain signals even when no structural damage is present. The marketing page states that 95% of sciatic nerve pain has nothing to do with bulging discs.

Research context: The concept that NAD+ decline affects neuronal health is supported by published research. However, “Sciatic Nerve Decay” is not a standardized medical diagnosis recognized in peer-reviewed literature. Sciatica has multiple documented causes, including disc herniation, spinal stenosis, piriformis syndrome, and other structural factors. The claim that 95% of cases are unrelated to disc issues does not align with mainstream orthopedic and neurological literature. The underlying biological concept draws from real science, but the specific framework represents the company’s positioning.

Company Claim: The cream delivers relief in 15 minutes through a three-phase process

The promotional page describes a “Refuel Phase,” an “Anti-Inflammation Phase,” and a “Stabilization Phase” occurring sequentially within 15 minutes of application.

Research context: No published clinical trial has evaluated whether Magnesium Niacinamide Relief produces measurable physiological changes within a 15-minute application window. Topical magnesium absorption has been studied, with results varying considerably depending on the magnesium compound, concentration, and application area. Some consumers may experience subjective comfort from topical application, but the structured three-phase timeline represents the company’s description of how the formula is designed to work — not a clinically validated outcome sequence.

Company Claim: Over 90% of users report significant relief within the first week

Research context: This figure appears in the company’s marketing materials and represents self-reported data that has not been independently verified through published research. The company’s promotional page also references a 0.4% refund rate, which the company presents as evidence of product satisfaction. Refund rate and satisfaction data from the company’s own reporting are not equivalent to clinical trial outcomes.

Company Claim: The formula is based on Nobel Prize-winning research

Research context: Dr. Rita Levi-Montalcini received the Nobel Prize in 1986 for her discovery of nerve growth factor (NGF). Her research on nerve cell development and degeneration is foundational to neuroscience. However, her Nobel Prize-winning work did not involve topical magnesium niacinamide cream, NAD+ supplementation, or the management of sciatica. Referencing her research provides scientific credibility to the broader biological concepts but does not constitute an endorsement of or connection to this specific product.

Pricing Disclosure

According to the company’s published checkout information at the time of this reporting, Magnesium Niacinamide Relief is offered in several package options:

6-Jar Package: According to the company, $29.99 per jar with shipping included
3-Jar Package: According to the company, $39.99 per jar with shipping included
1-Jar Package: According to the company, $49.99 per jar plus $9 shipping and handling

The company’s promotional materials also reference a standard price of $89 per jar. All purchases are described as one-time payments with no subscription or automatic rebilling. Pricing and availability may change. Consumers should verify current terms by viewing the current Magnesium Niacinamide Relief offer (official Peak Health Research page).

Refund Policy Analysis

According to the company’s published return policy, consumers are covered by a 180-day money-back guarantee. Per the published terms, consumers who are unsatisfied within the first 180 days of receiving their order can request a full refund of the purchase price.

There is a detail worth noting here. The company’s promotional page describes the guarantee as “no forms to fill out” and “no questions asked” with refunds arriving within 48 hours. The formal terms and conditions describe a more structured process: consumers must first contact customer service at (888) 811-1186 to obtain a Return Merchandise Authorization (RMA) number, then return the product within 15 days of receiving that number. According to the terms, customers are responsible for return shipping costs, shipments returned without RMA numbers may not be eligible for a refund, and processing may take up to 15 business days after the returned product is received.

Both descriptions come from the same company. Consumers should review the complete terms and conditions — not just the promotional page — when evaluating the refund policy. Holding on to purchase confirmation details is advisable.

Consumer Verification Checklist

If you are considering Magnesium Niacinamide Relief, here are the verification steps worth completing before ordering.

Discuss nerve discomfort with a healthcare provider first. Sciatic nerve pain can stem from multiple causes, some of which require medical imaging and professional treatment. A topical product is not a substitute for professional diagnosis, and persistent or worsening nerve pain should be evaluated by a qualified clinician.

Understand the difference between ingredient research and product trials. Magnesium, niacinamide, arnica, and boswellia each have published research histories. Those studies examined specific compounds at specific dosages under controlled conditions — not this finished product’s formulation. That distinction matters when interpreting marketing claims.

Review the refund terms carefully. The marketing page and the formal terms and conditions describe different refund experiences. Review the complete terms on the official website — including the RMA requirement, the 15-day return window after receiving your RMA number, and the processing timeline — before purchasing.

Verify pricing directly on the official site. The company’s promotional materials reference an $89 standard price alongside the tiered package pricing. Confirm current pricing at checkout before completing any purchase. Current terms are available by viewing the current Magnesium Niacinamide Relief offer (official Peak Health Research page).

Evaluate marketing urgency claims independently. The promotional materials reference limited inventory counts and time-limited pricing windows. These are common direct-response marketing techniques. Make purchasing decisions based on your own research timeline rather than external urgency.

Review the ingredient list for personal sensitivities. Consumers with sensitive skin or botanical allergies should review the complete ingredient list and discuss topical application with their healthcare provider, particularly if taking blood thinners or other medications that may interact with botanical compounds.

Consumer Fit Considerations

Situations Consumers May Wish to Consider:

Preference for topical application over oral supplements: Some people prefer applying products directly to the area of discomfort rather than taking capsules. Topical delivery is this product’s primary design feature.

Interest in exploring natural ingredient options alongside professional care: The formula contains botanical ingredients with individual research backgrounds. People who want to explore natural ingredient options as one component of a broader wellness approach — not as a replacement for medical treatment — may find the ingredient profile worth evaluating with their healthcare provider.

Interest in a product with a published return window: The 180-day guarantee, per the company’s published terms, provides a return window for consumers who do not experience the results they expected. Review the specific return process requirements before ordering.

Situations Where Additional Caution May Be Appropriate:

Need for transparent ingredient concentrations: The product’s individual ingredient dosages per application are not fully disclosed. Consumers who need specific concentration data to discuss with a healthcare provider or to compare against published research dosages may find this limiting.

Severe or worsening nerve pain: Persistent or worsening sciatic nerve pain may indicate an underlying condition requiring diagnostic imaging, professional evaluation, and prescribed treatment. A topical product is not a substitute for medical care.

Expectation that a single product can replace professional treatment: The company’s marketing positions the cream as an alternative to medications, injections, and surgery. Consumers should approach these positioning claims with appropriate caution and make treatment decisions in consultation with qualified healthcare providers rather than based on marketing materials alone.

Questions to Ask Yourself

Before choosing any topical nerve support product, consider these questions: Have you discussed your sciatic nerve discomfort with a qualified healthcare provider? Are you currently taking medications that could interact with topical magnesium or botanical ingredients? Have you had diagnostic imaging to identify the cause of your discomfort? Are you comfortable with a product where individual ingredient concentrations are not fully disclosed? These considerations may help consumers evaluate what additional information they want to verify before purchasing. For those who have completed their due diligence, current product details are available by viewing the current Magnesium Niacinamide Relief offer (official Peak Health Research page).

Frequently Asked Questions

Is Magnesium Niacinamide Relief FDA approved?

According to the company’s own disclaimer, the statements on its website have not been evaluated by the Food and Drug Administration, and the product is not intended to diagnose, treat, cure, or prevent any disease. As a topical product, it does not require FDA approval before being sold. The company states that the product is manufactured in an FDA-registered, GMP-certified facility — which relates to manufacturing standards rather than product approval or endorsement.

What is “Sciatic Nerve Decay”?

As used in the company’s marketing, “Sciatic Nerve Decay” describes a proposed condition in which nerve cells deteriorate due to declining NAD+ levels and nutrient deprivation. While age-related changes in NAD+ levels and nerve cell function are recognized areas of published research, the specific term is a marketing descriptor used by the company rather than a standardized medical diagnosis found in peer-reviewed literature.

Does topical NAD+ supplementation work for nerve pain?

NAD+ biology and its connection to neuronal health are well established in published research. However, most NAD+ supplementation studies have examined oral precursors such as NMN and NR, not topical niacinamide. The extent to which topically applied niacinamide reaches deep nerve tissue at meaningful concentrations has not been established through published clinical trials. Consumers searching for information on topical NAD+ nerve support should understand this distinction when evaluating marketing claims.

Can Magnesium Niacinamide Relief replace prescribed treatment?

According to the company’s own terms of service, the information on its website should not be used in place of advice from a healthcare provider. The terms state that the website does not recommend self-management of health problems. Consumers should not change, adjust, or discontinue any prescribed medications or treatments without their physician’s guidance.

Where is Magnesium Niacinamide Relief sold?

According to the company, the product is available exclusively through the official Peak Health Research website. The company’s marketing page states that the product is no longer sold on Amazon and warns against purchasing from unauthorized sellers due to concerns about counterfeit products.

What is the refund process?

According to the company’s published terms, consumers must contact customer service at (888) 811-1186 to obtain a Return Merchandise Authorization (RMA) number before returning the product. After receiving the RMA, consumers have 15 days to ship the product back. The company states that customers are responsible for return shipping costs. According to the published policy, refunds may take up to 15 business days after the returned product is received and processed.

Is Magnesium Niacinamide Relief the same as MagnesiumFreeze?

The product appears in consumer searches under both names, including “Magnesium Niacinamide Relief” and “MagnesiumFreeze.” Consumers should confirm the current product name, packaging, and official ordering page directly through the company’s published materials before purchasing.

Additional Consumer Research

Consumers researching MagnesiumFreeze and Magnesium Niacinamide Relief may benefit from reviewing previously published independent reporting on this product. A 2026 consumer research overview examining Magnesium Niacinamide Relief topical cream and what consumers are researching before buying provides additional context on the product’s positioning, ingredient background, and buyer considerations.

Evaluating multiple independent sources is recommended before making any purchasing decision. Consumers may also wish to review published research on NAD+ metabolism, topical magnesium absorption, and botanical anti-inflammatory compounds through peer-reviewed databases such as PubMed.

Contact Information

For questions before or during the ordering process, according to the company’s website, Peak Health Research offers customer support through the following channels:

Phone: (888) 811-1186
Email: support@peakhealthresearch.com
Mailing Address: Peak Health Research, 41 W Highway 14 STE 1763, Spearfish, SD 57783

Consumers who have completed their own research and want to review the full product details can do so. Complete product information, current pricing, and published terms are available by viewing the current Magnesium Niacinamide Relief offer (official Peak Health Research page).

Disclaimers

Content and Consumer Information Disclaimer: This article is an independent informational overview and does not constitute medical, health, or treatment advice. All product details, ingredient information, pricing, and policy terms described in this article are stated as presented by the company on its publicly available website and product labeling. This content has not been independently audited or verified unless specifically noted. Readers are encouraged to verify all claims directly with the manufacturer and to consult a qualified healthcare professional before beginning any topical product.

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. Magnesium Niacinamide Relief is a topical cream, not a medication. If you are currently taking medications, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting Magnesium Niacinamide Relief or any new product. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, the nature and severity of nerve discomfort, skin absorption characteristics, consistency of use, genetic factors, current medications, and other individual variables. While some customers report improvements, results are not guaranteed. These are individual experiences and should not be interpreted as typical or guaranteed results.

FTC Affiliate Disclosure: If a purchase is made through links in this article, a commission may be earned at no additional cost to the buyer. All descriptions are based on published research and publicly available information.

Pricing Disclaimer: All pricing information referenced was based on the company’s published website information at the time of publication (March 2026) and is subject to change without notice. Always verify current pricing and terms on the official Peak Health Research website before making any purchasing decision.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. The publisher does not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Readers are encouraged to verify all details directly with Peak Health Research and their healthcare provider before making decisions.

CONTACT: Phone: (888) 811-1186
Email: support@peakhealthresearch.com

AIM ImmunoTech Announces Closing of its Rights Offering




AIM ImmunoTech Announces Closing of its Rights Offering

OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today the closing of its previously announced rights offering (the “Rights Offering”). The Rights Offering resulted in total subscriptions of approximately $1.8 million.

Each right entitled the holder to purchase one unit (“Unit”), at a subscription price of $1,000 per Unit, consisting of one share of the Company’s Series G Convertible Preferred Stock (the “Preferred Stock”), and 2,000 Class G Common Stock Purchase Warrants to purchase the Company’s Common Stock (the “Warrants”).

Maxim Group LLC acted as dealer-manager for the Rights Offering.

The Company’s registration statement on Form S-1 (Registration No. 333-292085) was declared effective by the Securities and Exchange Commission (“SEC”) on February 10, 2026, as modified by the prospectus supplement filed with the SEC on February 27, 2026. The prospectus relating to and describing the terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC’s website at https://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

Forward Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in the Company’s reports filed with the SEC on its website and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and the registration statement. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

CONTACT: IR Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.




Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share

Board of directors unanimously approved the transaction and recommends that stockholders tender their shares

Transaction expected to close in the second quarter of 2026

BASKING RIDGE, N.J., March 06, 2026 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a definitive agreement to be acquired by Kuva Labs Inc. (”Kuva”), a privately-held company.

Details of the Transaction

Under the terms of the merger agreement, Kuva will commence a tender offer to acquire all the issued and outstanding shares of common stock of the Company for $5.00 per share in cash payable at closing plus one contingent value right (“CVR”) per share (the “Transaction”). The CVR entitles the holders of record to receive an additional cash payment of $1.00 per share if a New Drug Application or similar registration is filed or formally accepted for review by the FDA or any governmental authority in any jurisdiction with respect to any pharmaceutical product that contains or incorporates the product candidate referred to as of the date of the merger agreement as certepetide for any indication or patient population prior to the earlier of (a) 11:59 p.m. New York City Time on the seventh (7th) anniversary of the closing date, and (b) termination of the CVR agreement. Should the relevant milestone not be met, then no additional consideration will be payable to the holders of the CVRs in relation to such milestone.

The Transaction is subject to customary offer conditions contained in the merger agreement that will be filed with the SEC, including the tender of a majority of the outstanding shares of the Company’s capital stock. The merger agreement does not include a financing condition. The Transaction is expected to close in the second quarter of 2026, subject to satisfaction of the offer conditions. If the tender offer closes, then Kuva would acquire the untendered shares and convertible securities of the Company through a second-step merger for the same consideration.

Following completion of the Transaction, Lisata will become part of Kuva, a privately-held company, and its common stock will be delisted from the Nasdaq Capital Market. Lisata will also apply to deregister its common stock and cease to be a reporting company under the United States Securities Exchange Act of 1934, as amended.

Board of Directors Recommendation

Following a comprehensive strategic review and thorough evaluation conducted with the assistance of its independent legal and financial advisors, the Lisata board of directors has unanimously determined that the definitive agreement and the transactions contemplated thereby are advisable, fair to, and in the best interests of Lisata and its stockholders. The board of directors has duly authorized and approved the execution and delivery of the merger agreement and unanimously recommends that all stockholders accept the offer and tender their shares.

Advisors

Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. is serving as legal counsel to Lisata and H.C. Wainwright & Co. acted as financial advisor to Lisata. Goodwin Procter LLP is acting as legal counsel to Kuva.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform^® technology. For a comprehensive overview of certepetide’s mechanism of action, please view our informative short film. For more information on the Company and to access the short film, please visit www.lisata.com.

About Kuva Labs

Kuva Labs is a preclinical bioscience company developing the proprietary NanoMark™ direct MR imaging platform. Kuva was founded in 2019, after its founders experienced tragic losses in cancer cases which could have been prevented with better tools. Kuva is seeking to transform the way cancer is seen and ultimately treated. This technology enables the selective and unambiguous imaging of solid tumors with the highest contrast and spatial resolution without the use of ionizing radiation. This information speeds both accurate diagnosis and treatment – delivering better and quicker clinical intervention and better overall outcomes. For more information, please visit www.kuvalabs.com.

Additional Information and Where to Find It

The tender offer referred to in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Kuva and Kuva Acquisition Corp., a wholly owned subsidiary of Kuva (“Purchaser”) will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Kuva and Purchaser will cause to be filed a tender offer statement on Schedule TO with the SEC, and Lisata will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer.

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF LISATA ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE OFFER.

Both the tender offer statement and the solicitation/recommendation statement will be mailed to Lisata’s stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of Lisata by accessing https://ir.lisata.com or by contacting Investor Relations at 908-842-0084. In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at no charge on the SEC’s website: www.sec.gov, upon filing with the SEC.

LISATA’S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.

Cautionary Note Regarding Forward-Looking Statements

This document includes forward-looking statements that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, statements regarding the proposed acquisition of Lisata by Kuva, the expected timetable for completing the transaction, and Lisata’s future financial or operating performance. These forward-looking statements typically can be identified by words such as “believe,” “expect,” “estimate,” “predict,” “target,” “potential,” “likely,” “continue,” “ongoing,” “could,” “should,” “intend,” “may,” “might,” “plan,” “seek,” “anticipate,” “project” and similar expressions, as well as variations or negatives of these words. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of Lisata by Kuva, similar transactions, prospective performance, future plans, events, expectations, objectives, opportunities, and the outlook for Lisata; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties; accordingly, investors are cautioned not to place undue reliance on forward-looking statements. Actual results may differ materially due to several factors. Factors that could cause future results to differ materially include: risks associated with the timing of the closing of the proposed transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed transaction will not occur; uncertainties as to how many of Lisata’s stockholders will tender their shares in the offer; the possibility that competing offers will be made; the occurrence of any event, change, or other circumstance that could give rise to the termination of the Merger Agreement, including circumstances requiring the Company to pay a termination fee pursuant to the Merger Agreement; the outcome of any legal proceedings that may be instituted against the parties and others related to the Merger Agreement; unanticipated difficulties or expenditures relating to the proposed transaction; the response of business partners to the announcement of the proposed transaction, and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction; the possibility that the milestone payment related to the CVR will never be achieved and that no milestone payment may be made; the risk that any equityholder litigation in connection with the proposed transactions may result in significant costs of defense, indemnification and liability; Lisata’s ability to successfully demonstrate the efficacy and safety of its product candidates, and the preclinical or clinical results for its product candidates, which may not support further development of such product candidates; comments, feedback and actions of regulatory agencies; Lisata’s dependence on the successful clinical development, regulatory approval and commercialization of its product candidates; the inherent uncertainties associated with developing new products or technologies and operating as clinical stage company; the Company’s cash sufficiency and runway; and other risks identified in Lisata’s SEC filings, including Lisata’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025 and subsequent filings with the SEC. Lisata cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The forward-looking statements in this document speak only as of the date of this document. Lisata undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

Contact:

Media and Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com

This press release was published by a CLEAR® Verified individual.

Curaechoice and Health Benefit Alliance Partner to Deliver No-Cost Healthcare to 161,000 Members Across 42 States




Curaechoice and Health Benefit Alliance Partner to Deliver No-Cost Healthcare to 161,000 Members Across 42 States

Strategic collaboration expands access to $0 medical, pharmacy, dental, and vision benefits for more than 1,000 self-insured employers nationwide

Birmingham, ALABAMA, March 06, 2026 (GLOBE NEWSWIRE) — Curaechoice, the nation’s leading No-Cost Benefits Optimization platform, today announced a strategic partnership with the Health Benefit Alliance (HBA) to expand access to comprehensive, affordable healthcare solutions for employers and their employees across the United States.

The Health Benefit Alliance is dedicated to removing barriers to healthcare so individuals and families can access coverage when they need it most. The mission aligns closely with Curaechoice’s commitment to no-cost healthcare, eliminating copays, deductibles, and coinsurance across medical, pharmacy, dental, and vision benefits for employees and their families.

Through this partnership, HBA will introduce Curaechoice’s No-Cost Healthcare model as an additional benefit option for more than 1,023 self-insured employers representing approximately 161,000 qualified members across 42 states. The collaboration provides employers with a scalable, ready-to-implement side by side solution designed to simplify healthcare without disrupting existing coverage strategies.

“Our mission has always been to remove barriers that prevent individuals and families from accessing the care they need,” said Matt Esposito, President of the Health Benefit Alliance. “Partnering with Curaechoice is a true win-win, strengthening the solutions we can offer employers by introducing a proven no-cost model that delivers comprehensive coverage without the financial burden traditionally associated with healthcare.”

Highlights of the Curaechoice–HBA partnership include:

Curaechoice Medical – Access to more than 500 medical specialties and subspecialties, including hospital care, cancer treatment, joint replacement, dermatology, urgent care, and mental health services—supporting both preventive and chronic care – at no cost.

Curaechoice Pharmacy – No-cost prescription access at 65,000 pharmacies nationwide, including major retail chains. Employers benefit from no PEPM fees, valuable clinical and utilization monitoring tools, and no-delay employer rebates processed at the point of sale for maximum transparency and immediate savings.

Curaechoice Vision – Access to more than 26,000 vision centers nationwide, providing routine eye exams, lenses, and frames at no cost.

Curaechoice Dental – Access to essential and specialized dental services designed to support preventive and long-term oral health at no cost.

Healthcare affordability remains a major concern for working families. According to the Kaiser Family Foundation, 60% of employees with employer-sponsored insurance expect healthcare to become less affordable, and more than two-thirds of adults report concerns about paying for healthcare services.

“Employers across the country are searching for solutions that address rising healthcare costs without sacrificing access to care,” said Harsha Hatti, CEO of Curaechoice. “Our partnership with the Health Benefit Alliance reflects our shared mission to making healthcare simple, accessible, and affordable while removing financial barriers for employees and their families.”

About Health Benefit Alliance (HBA)

Headquartered in Norwalk, CT. The Health Benefit Alliance delivers efficient, affordable, and compliant health benefit solutions for employers nationwide. HBA’s integrated plan designs emphasize zero-deductible and low copay structures, and PPO network options. With a steadfast commitment to access, affordability, and performance, HBA helps clients offer valuable, easy-to-use benefits that attract and retain talent while controlling costs.

Learn more at www.healthbenefitalliance.com

About Curaechoice

Curaechoice is the leading No-Cost Benefits Optimization platform partnering with self-insured employers to deliver comprehensive healthcare coverage with $0 copays, $0 deductibles, and $0 coinsurance across medical, pharmacy, dental, and vision benefits. Through its dual-patented technology, Curaechoice simplifies healthcare while improving access and affordability.
Learn more at www.curaechoice.com.

Press Inquiries

Curaechoice Media
media [at] curaechoice.com
800-646-9823
https://curaechoice.com
3179 Green Valley Rd PMB 634
Birmingham, AL 35243

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 06, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics’ Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics’ 2023 Inducement Plan.

The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual’s entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $11.94 per share, which is equal to the closing price of Tango Therapeutics’ common stock on February 2, 2026. Each option will vest as to 25% of the shares underlying such option on February 2, 2027 and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to such employee’s continued employment on each vesting date. The RSU award will vest as to: (i) 20,000 shares on or about February 1, 2027, (ii) 20,000 shares on or about February 14, 2028, and (iii) 20,000 shares on or about February 12, 2029, subject to such employee’s continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics’ 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com

Harvard Bioscience Announces Reverse Stock Split




Harvard Bioscience Announces Reverse Stock Split

• Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026

HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a global leader in life science research tools, today announced that its board of directors approved the Company’s 1-for-10 reverse stock split (the “Reverse Split”) of the Company’s common stock, par value $0.01 per share. The Reverse Split was approved by the stockholders of the Company at a special meeting held on March 6, 2026.

The Reverse Split will legally take effect at 4:30 p.m. Eastern Time, on March 13, 2026. The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

The 1-for-10 Reverse Split will automatically convert every 10 current shares of the Company’s common stock into one share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of the Company’s common stock following the Reverse Split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the Reverse Split, on March 13, 2026.

The Reverse Split will reduce the number of shares of outstanding common stock from approximately 44,719,894 shares, to approximately 4,471,989 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company’s outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company’s stock incentive plans.

Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers’ particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Computershare Inc., will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.

Additional information regarding the Reverse Stock Split is available in the Company’s definitive proxy statement originally filed with the U.S. Securities and Exchange Commission (SEC) on January 30, 2026.

About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, statements concerning the sustainability of the Company’s ability to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market, its capital structure, its lower near-term refinancing risk and path toward long-term deleveraging, expected future financial and operational performance, the strength of the Company’s market position, business model and anticipated macroeconomic conditions, and matters relating to our ability to continue as a going concern, fund our operations, or comply with the terms of our credit agreement. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as filed with the Securities and Exchange Commission (“SEC”), as well as in the Company’s other filings with the SEC. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Harvard Bioscience Investor Inquiries:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com

VALNEVA Declaration of shares and voting rights: February 28, 2026




VALNEVA Declaration of shares and voting rights: February 28, 2026

VALNEVA

Declaration of shares and voting rights
February 28, 2026
__________________________________________________________________________________________

Company name: VALNEVA
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon
Regulated market of Euronext Paris – Compartment B

Declaration date: March 6, 2026

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
** Net (or exercisable at a General Meeting) voting rights.

Attachment

• 2026_03_06 DECLARATION_VOTING_RIGHTS February 28, 2026 EN_GN

EssilorLuxottica: 2025 Universal Registration Document filed




EssilorLuxottica: 2025 Universal Registration Document filed

2025 Universal Registration Document filed

Paris, France (6 March 2026) – EssilorLuxottica announces the availability of its 2025 Universal Registration Document, in accordance with applicable regulation. The French version of this document, prepared in ESEF format (European Single Electronic Format), was filed with the Autorité des Marchés Financiers (AMF, the French market regulator) on March 6, 2026 under the reference D.26-0067.

The Universal Registration Document includes, in particular, the Annual Financial Report, with:

• The parent Company Financial Statements;
• The Group Consolidated Financial Statements;
• The Management Report and the Vigilance Plan, in compliance with articles L.225-100 and L.225-102-1 respectively of the French Commercial Code, as well as the Report on Corporate Governance as per article L.225-37 of the French Commercial Code and the Sustainability Report as per article L.233-28-4 of the French Commercial Code;
• A statement by the person responsible for the Universal Registration Document;
• The Statutory Auditors’ Reports on the parent Company and on the Group Consolidated Financial Statements, as well as the Report on the Certification of Sustainability Information; and
• Information concerning Statutory Auditors’ fees.

The French version of the Universal Registration Document and its English translation are available to the public free of charge, as provided for by the applicable legislation, and may be downloaded from EssilorLuxottica corporate website.

Attachment

• DOWNLOAD THE PRESS RELEASE

Nika Pharmaceuticals, Inc. (NIKA) Signed a Consultancy Agreement with MD Global Partners LLC




Nika Pharmaceuticals, Inc. (NIKA) Signed a Consultancy Agreement with MD Global Partners LLC

HENDERSON, Nev., March 06, 2026 (GLOBE NEWSWIRE) — Nika Pharmaceuticals, Inc. (OTCQB: NIKA) announces that it has signed a consultancy agreement with MD Global Partners LLC, a leading Manhattan-based investment bank. MD Global will provide NIKA with various services, which may include, but are not limited to assistance in capital raising efforts, growth initiatives, and conducting due diligence on potential transactions.

“As we prepare for the next stages of our development, it is important that we have an advisor with proven track record and expertise”, stated Dimitar Savov, CEO of NIKA. “We expect significant growth once the production factory is operational and distribution begins, so the experience of MD Global Partners will be an important asset to our company. I believe that this is the start of a valuable long-term partnership,” concluded Savov.

About Nika Pharmaceuticals, Inc.

Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA’s intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.

Forward-looking Statement:

This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “estimates,” “projects,” “intends,” “plan,” “can,” “will,” “would,” “expects,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.

CONTACT: CONTACT Clifford Redekop, Secretary
COMPANY Nika Pharmaceuticals, Inc.
PHONE (702)-326-3615
EMAIL info@nikapharmaceuticals.com
WEB www.nikapharmaceuticals.com